Karuna Therapeutics’ NDA for KarXT accepted by USFDA
If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
clinical study
Leiden University Medica Center and Intravacc to start clinical trial with new intranasal corona…
Nasal spray vaccine based on soluble nano-spheres with synthetic corona proteins
Biocon Biologics initiates clinical study for Itolizumab in Lupus Nephritis
Equalise is a phase-Ib open-label, proof-of-concept clinical study currently studying Lupus Nephritis patients in the Part B…
Pycnogenol® for cognitive function at every stage of life
Franziska Weichmann, Manager of Scientific Communications and Product Development, HORPHAG informs that Pycnogenol® has shown a…
Himalaya study finds herbal immunomodulators effective as adjuvant treatment for COVID-19
The study states that adjuvant therapy with Septilin and Bresol along with SOC supports immunity and controls inflammation in…
Piramal Pharma Solutions to provide Bolt Biotherapeutics with immune-stimulating antibody conjugates…
Bolt’s Boltbody Immune Stimulating Antibody Conjugate (ISAC), BDC-1001, is currently in a first-in-human Phase 1/2 clinical study…
Vaccitech begins Phase 1 clinical study of VTP-300 immunotherapeutic to treat chronic Hepatitis B
Once the VTP-300 prime dose is confirmed, Vaccitech plans to initiate a Phase 1b/2a study, HBV002, in Q3 2020